Medicare offers $50 GLP-1 weight-loss drugs to millions through a 2026–2027 Bridge program
TL;DR
Medicare's short-term GLP-1 Bridge program (July 2026–Dec 2027) will allow up to 14 million overweight beneficiaries to obtain weight-loss GLP-1 medications (Zepbound, Foundayo, Wegovy) for a $50 monthly copay, with Ozempic excluded; eligibility requires 65+ age and BMI criteria (BMI 35+ or 27+ with obesity-related conditions) and Part D enrollment, plus a doctor’s prior authorization via Humana. The initiative hinges on insurer participation for a longer-term rollout and carries an estimated price tag of billions through 2034; it does not include counseling components, and weight regain may occur after stopping the drug.
- Up to 14M Medicare patients could be eligible for GLP-1s for just $50 a month — here's who qualifies New York Post
- Pharmalittle: We're reading about Medicare and obesity drugs, Germany's pricing plans, and more statnews.com
- Medicare's GLP-1 Program Looms; Chemicals in Breast Milk; Acromegaly Drug Rejected MedPage Today
Want the full story? Read the original reporting
Read on New York Post